These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802 [TBL] [Abstract][Full Text] [Related]
9. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schömig A; Mehilli J; J Am Coll Cardiol; 2011 Sep; 58(13):1325-31. PubMed ID: 21920260 [TBL] [Abstract][Full Text] [Related]
10. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. Waksman R; Pakala R EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674 [TBL] [Abstract][Full Text] [Related]
11. Engineering aspects of stents design and their translation into clinical practice. Sangiorgi G; Melzi G; Agostoni P; Cola C; Clementi F; Romitelli P; Virmani R; Colombo A Ann Ist Super Sanita; 2007; 43(1):89-100. PubMed ID: 17536159 [TBL] [Abstract][Full Text] [Related]
12. The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. Saito Y; Grubman D; Cristea E; Lansky A Cardiol Rev; 2020; 28(4):208-212. PubMed ID: 32032131 [TBL] [Abstract][Full Text] [Related]
13. DES the year in review: controversies. Garg S; Bourantas C; Serruys PW Minerva Cardioangiol; 2013 Apr; 61(2):99-123. PubMed ID: 23492595 [TBL] [Abstract][Full Text] [Related]
14. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study. Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312 [TBL] [Abstract][Full Text] [Related]
15. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry]. Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J; Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439 [TBL] [Abstract][Full Text] [Related]
16. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066 [TBL] [Abstract][Full Text] [Related]
17. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. Grube E; Buellesfeld L Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588 [TBL] [Abstract][Full Text] [Related]
18. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925 [TBL] [Abstract][Full Text] [Related]
19. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736 [TBL] [Abstract][Full Text] [Related]